Faron Pharma primed for a pivotal period in its development
The company is more advanced than many of its AIM compatriots, with a drug undergoing Phase III clinical trials
Company
Faron Pharmaceuticals Limited
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
418 stories · page 19 of 21
FTSE 100 closes lower as traders continue to fret about North Korea
FTSE 100 closed down 18.79 at 7,354, while the FTSE 250 lost over 74 points at 19,652.
Archive
Sports Direct chairman faces the boot at AGM on busy day of updates from housebuilders
Sports Direct’s AGM and earnings from housebuilders will take centre stage on Wednesday
Archive
Proactive news snapshot: 88 Energy, Sound Energy, Sunrise Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Faron Pharma gets a boost as FDA says can use outside US trial data for Traumakine license application
Dr Markku Jalkanen, Faron's CEO, said: "This important feedback potentially speeds up the regulatory approval process in the US and brings us one step closer to delivering Traumakine to patients in the world's largest pharmaceutical market“
Archive
Barrage of builders to update in week ahead with Brexit concerns remaining key
Week ahead includes updates from a raft of housebuilders, including Barratt Developments, Berkeley Group and Bovis Homes, plus trading news from Halfords Group, and the latest European Central Bank Council meeting
Archive
Proactive news snapshot – Porta Communications, S & U, FairFX…
Some of the day's highlights from the Proactive newswire...
Petrofac gets Oman contract boost; Anglo African Oil & Gas up on acquisition completion
A look at some of the biggest risers and faller in London today ...
Faron Pharma to provide drug compassionate use of drug; data monitors green light study as it moves into its final few months
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
FTSE 100 receives boost from US jobless figures
The blue-chip index closed at 7,512, up 37 points on the day and 143 on the week
Faron Pharma weak on profit-taking after an uninspiring report on ongoing phase III trials
Analyst Julie Simmonds at broker Panmure Gordon said: “No negative or positive read through on the likely outcome of the trial can be made from the statement”
FTSE 100 firm but off highs as New York makes dull early progress
With around an hour and a half of trading to go in London, the FTSE 100 was up about 11 points at 7,308, holding off the day’s peak of 7,322
Archive
Proactive news round-up: Lombard Risk Management, Acal, Symphony Environmental Technologies …
A glance at some of the stories on the Proactive newswire today
Lombard Risk Management surges after raising guidance
Lombard Risk provided further evidence that its turnaround plan is gaining momentum
Drug developer Faron Pharmaceuticals to appoint two industry heavyweights to the board
Dr Gregory Brown and John Poulos bring with them a breadth and depth of industry experience
FTSE 100 closes down as May wins MP backing for election
Although it has been an up and down day for the Footsie, it has rarely strayed far from last night's closing level
Archive
Proactive news round-up: SDX Energy, Motif Bio, Sound Energy…
A glance at some of the stories on the Proactive newswire today